Ionis Pharmaceuticals (IONS) Misses Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ionis Pharmaceuticals (IONS) PT Lowered to $60 at Needham & Company
November 4, 2021 7:28 AM EDTNeedham & Company analyst Chad Messer lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $60.00 (from $84.00) while maintaining a Buy rating.
The analyst commented, "IONS reported 3Q21 financial results yesterday, and we spoke w/ mgmt for additional details. Partner BIIB (not rated) previously... More
